These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 23900411)

  • 21. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropathological correlates of parkinsonian disorders in a large Dutch autopsy series.
    Geut H; Hepp DH; Foncke E; Berendse HW; Rozemuller JM; Huitinga I; van de Berg WDJ
    Acta Neuropathol Commun; 2020 Mar; 8(1):39. PubMed ID: 32216828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
    Sierra M; Gelpi E; Martí MJ; Compta Y
    Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.
    Irwin DJ; Grossman M; Weintraub D; Hurtig HI; Duda JE; Xie SX; Lee EB; Van Deerlin VM; Lopez OL; Kofler JK; Nelson PT; Jicha GA; Woltjer R; Quinn JF; Kaye J; Leverenz JB; Tsuang D; Longfellow K; Yearout D; Kukull W; Keene CD; Montine TJ; Zabetian CP; Trojanowski JQ
    Lancet Neurol; 2017 Jan; 16(1):55-65. PubMed ID: 27979356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia.
    Chiu PY; Yang FC; Chiu MJ; Lin WC; Lu CH; Yang SY
    Sci Rep; 2022 Oct; 12(1):17919. PubMed ID: 36289355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lewy body pathology in Alzheimer's disease.
    Kotzbauer PT; Trojanowsk JQ; Lee VM
    J Mol Neurosci; 2001 Oct; 17(2):225-32. PubMed ID: 11816795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
    Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
    Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aluminum and Neurofibrillary Tangle Co-Localization in Familial Alzheimer's Disease and Related Neurological Disorders.
    Mold MJ; O'Farrell A; Morris B; Exley C
    J Alzheimers Dis; 2020; 78(1):139-149. PubMed ID: 32925074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
    Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
    Coskuner-Weber O; Uversky VN
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
    Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
    Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
    Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
    Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients.
    Doorn KJ; Goudriaan A; Blits-Huizinga C; Bol JG; Rozemuller AJ; Hoogland PV; Lucassen PJ; Drukarch B; van de Berg WD; van Dam AM
    Brain Pathol; 2014 Mar; 24(2):152-65. PubMed ID: 24033473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mixed pathology as a rule, not exception: Time to reconsider disease nosology.
    Chu Y; Hirst WD; Kordower JH
    Handb Clin Neurol; 2023; 192():57-71. PubMed ID: 36796948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
    Jellinger KA
    J Neural Transm (Vienna); 2018 Apr; 125(4):615-650. PubMed ID: 29222591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
    Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET Radiopharmaceuticals for Alzheimer's Disease and Parkinson's Disease Diagnosis, the Current and Future Landscape.
    Uzuegbunam BC; Librizzi D; Hooshyar Yousefi B
    Molecules; 2020 Feb; 25(4):. PubMed ID: 32098280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.